Objective. The pathogenesis of osteoarthritis (OA) includes both mechanical and inflammatory features. Studies have implicated synovial fluid uric acid (UA) as a potential OA biomarker, possibly reflecting chondrocyte damage. Whether serum UA levels reflect/contribute to OA is unknown. We investigated whether serum UA levels predict OA progression in a non-gout knee OA population.
Objective. The pathogenesis of osteoarthritis (OA) includes both mechanical and inflammatory features. Studies have implicated synovial fluid uric acid (UA) as a potential OA biomarker, possibly reflecting chondrocyte damage. Whether serum UA levels reflect/contribute to OA is unknown. We investigated whether serum UA levels predict OA progression in a non-gout knee OA population.
Methods. Eighty-eight patients with medial knee OA (body mass index [BMI] <33 kg/m 2 ) but without gout were studied. Baseline serum UA levels were measured in previously banked serum samples. At 0 and 24 months, patients underwent standardized weight-bearing fixedflexion posteroanterior knee radiography to determine joint space width (JSW) and Kellgren/Lawrence grades. Joint space narrowing (JSN) was calculated as the change in JSW from 0 to 24 months. Twenty-seven patients underwent baseline contrast-enhanced 3T knee magnetic resonance imaging for assessment of synovial volume.
Results. Serum UA levels correlated with JSN values in both univariate (r 5 0.40, P < 0.01) and multivariate (r 5 0.28, P 5 0.01) analyses. There was a significant difference in mean JSN after dichotomization at a serum UA cut point of 6.8 mg/dl, the solubility point for serum urate, even after adjustment (JSN of 0.90 mm for a serum UA ‡6.8 mg/dl and 0.31 mm for a serum UA <6.8 mg/dl; P < 0.01). Baseline serum UA levels distinguished progressors (JSN >0.2 mm) and fast progressors (JSN >0.5 mm) from nonprogressors (JSN £0.0 mm) in multivariate analyses (area under the receiver operating characteristic curve 0.63 [P 5 0.03] and 0.62 [P 5 0.05], respectively). Serum UA levels correlated with the synovial volume (r 5 0.44, P < 0.01), a possible marker of JSN, although this correlation did not persist after controlling for age, sex, and BMI (r 5 0.13, P 5 0.56).
Conclusion. In non-gout patients with knee OA, the serum UA level predicted future JSN and may serve as a biomarker for OA progression.
Osteoarthritis (OA), the most prevalent form of arthritis, remains poorly understood. Though historically regarded as a disease of mechanical degeneration, it is now appreciated that inflammation, on both the tissue and biochemical levels, plays an important role in OA pathogenesis (1) (2) (3) (4) . Various inflammatory molecules have been studied for their ability to reflect the presence of OA or predict its progression. For example, levels of 15-hydroxyeicosatetraenoic acid and prostaglandin E 2 are elevated in patients with symptomatic knee OA, and interleukin-1b (IL-1b) and IL-1 receptor antagonist have been reported to be associated with joint space narrowing (JSN) (5-7). The potential for these molecules to serve as OA biomarkers is a matter of ongoing investigation. In addition to prognostic utility, biomarkers that predict JSN would be of considerable value when defining enrollment criteria for prospective OA clinical trials, in which limiting heterogeneity and enriching for more rapid disease progression would have significant practical benefit (8) .
Uric acid (UA) is the end product of human purine catabolism, and in the form of soluble serum urate, it has been recognized as a biomarker in diseases such as heart failure, hypertension, and renal disease (9, 10) . UA is metabolically active and has been reported to act both intracellularly and extracellularly and to denote and/or promote inflammatory states (11) . In addition, UA precipitates monosodium urate monohydrate (MSU) crystals (in macroscopic or microscopic forms) and drives inflammation by engaging and activating leukocytes and other cells (12) . MSU crystals are responsible for not only the acute, painful attacks of gout, but also the lower-level, chronic inflammatory states (13) .
A small but accumulating body of evidence suggests that UA may participate in the pathogenesis of OA (14) . Previous reports noted an association between UA and OA (15) . Gout and OA often colocalize within the same joint (16) , and studies have shown that, even in the absence of gout, synovial fluid UA levels correlate with OA severity (17, 18) . We have reported that patients with gout are more likely than control subjects with a serum UA of ,6.8 mg/dl and no gout to have OA, with hyperuricemic non-gout patients having an intermediate level of knee OA prevalence and severity. When present, OA is also likely to be more severe in patients with gout as compared to those without it (19) .
Whether serum UA may serve as a biomarker to convey or predict OA risk is not known. To assess this possibility, we investigated whether serum UA levels are associated with the radiographic severity of knee OA and with synovial volume, as determined by contrast-enhanced magnetic resonance imaging (MRI), and whether serum UA levels predict OA JSN, in a non-gout population with knee OA.
PATIENTS AND METHODS
Patient population. We assessed a subset of patients enrolled in a previously described, 24-month prospective, natural history study of knee OA with a focus on inflammatory biomarker discovery. At initial enrollment, patients met the American College of Rheumatology (ACR) clinical criteria for knee OA (20) and had symptomatic OA of at least 1 knee (index knee), with a Kellgren/Lawrence (K/L) score of $1 in that knee (21) . Exclusion criteria included any other form of arthritis (e.g., rheumatoid arthritis, spondyloarthritis, gout, pyrophosphate disease, or other crystal arthropathy), a body mass index (BMI) $33 kg/m 2 (chosen to minimize the impact of obesity on OA/inflammatory biomarkers without adversely impairing recruitment potential), and other characteristics as previously described (7) . For the current study, we included only patients whose baseline knee OA was predominantly medial (i.e., medial joint space width [JSW] less than lateral JSW on radiographic assessment), consistent with the Osteoarthritis Research Society International recommendations (22) . Study patients additionally had both baseline and 24-month radiographic measurements, as well as stored serum samples available for baseline serum UA measurement. The study was approved by the Institutional review Board of New York University Medical Center, and informed consent had previously been obtained from all patients.
Clinical and laboratory assessments. All patients completed pain assessments by visual analog scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) (23) at baseline and every 6 months thereafter for the duration of the study. Pain questions were specific to the more painful knee (index knee). Blood samples from patients had been collected in serum collection tubes, and serum had been isolated within 60 minutes of collection. Serum samples were placed in aliquots and stored at 2708C until thawing for assessment of serum UA levels. Serum UA measurements were performed by the New York University Hospitals Clinical Laboratory and were determined by automated colorimetric assay using a Vitros analyzer (Ortho Clinical Diagnostics).
Radiographic and MRI measurements. All patients underwent weight-bearing, fixed-flexion posteroanterior knee radiography, which was performed in a standardized manner using a SynaFlexer radiographic positioning frame (Synarc), at baseline and at 24 months, as previously described (24) . Beam position was optimized for the medial joint space compartment. The patient's index knee was evaluated radiographically with respect to both K/L grade and medial JSW, the latter measured at the mid-portion of the joint space using electronic calipers. Lateral joint space width was also assessed. JSN was calculated as the change in JSW (in millimeters) from baseline to the month 24 follow-up. All baseline radiographs were read and measured by 2 experienced musculoskeletal radiologists (LR and JB) who were blinded with regard to the patient's identity and clinical information. There was a high correlation between readers (kappa values for interrater agreement were 0.85 and 0.77 for the K/L scores in the right and left knees, respectively, and kappa scores for JSW were $0.93 for the medial compartments of both the right and left knees). Based on the high interreader correlations, a single reader (LR) was used for assessing the 24-month follow-up results.
A subset of patients enrolled in the parent study (n 5 58) had undergone a dynamic gadolinium-enhanced 3.0T MRI of the index knee at baseline that was read for quantitative synovial volume. Of these patients, 27 met our additional requirements for the current study and were analyzed. The complete technical details of the MRI evaluation and the criteria for initial inclusion into the MRI assessment have been previously described (24) . Briefly, the precontrast portion of the imaging protocol included a sagittal 3-dimensional (3-D) high-resolution T1-weighted fast low-angle shoot (FLASH) sequence with selective water excitation, as well as a sagittal T2-weighted fat-saturated spin-echo sequence. The postcontrast portion of the examination consisted of a dynamic gadolinium-enhanced 3-D T1-weighted FLASH sequence obtained in the sagittal plane. Assessment of the synovial volume was performed with MatLab custom tools for manual segmentation of the entire knee joint, using contrast-enhanced dynamic images of the knees in relation to the precontrast images obtained at baseline. Patterns of signal enhancement were evaluated in the infrapatellar and suprapatellar fat pads, in the intercondylar notch, and along the periphery of joint effusion. All MRIs were evaluated in a blinded manner by a single expert reader (RR).
Outcomes and analysis. Our primary objective was to determine whether baseline serum UA levels are associated with medial JSN over 2 years. Secondary outcomes included the association of baseline serum UA levels with the baseline K/L grade, JSW, synovial volume on dynamic enhanced contrast MRI, and pain scores by VAS and WOMAC.
Statistical analysis. The relationships between baseline serum UA levels and clinical and demographic variables, including WOMAC pain, VAS pain, JSW, MRI-determined baseline synovial volume, age, and BMI, were determined by Pearson's correlation. Associations between serum UA and MRI-determined synovial volume were assessed by partial correlations, controlling for age, sex, and BMI. Given the limited number of patients in our analyses of MRI-determined synovial volume, this patient sample was assessed for normality in multiple ways. We confirmed a normal distribution on quantile-quantile plot, Lilliefors test (P 5 0.14), and square root transforms of the data, applying Lilliefors (P 5 0.50) and Shapiro-Wilk's (P 5 0.29) tests. However, Shapiro-Wilk's test on untransformed data did not support normality (P 5 0.01). Given that most, but not all, test results supported normality, MRI-determined synovial volume was interpreted as generally, but not strongly, normal in distribution.
The relationship between serum UA levels and binary baseline clinical and demographic variables, including diuretic intake and sex, were determined by Student's t-test. To analyze the relationship between serum UA and JSN, correlations were computed with and without controlling for age, sex, and BMI. Additionally, thresholds were chosen to examine the potential difference in JSN at different serum UA cut points (serum UA population median for the sample 5.85 mg/dl), ACR treatment target (6.0 mg/dl), and the solubility threshold for urate (6.8 mg/ dl), as assessed by Student's t-test. One-way analysis of variance (ANOVA) was used to examine the potential differences in serum UA levels among patients defined as having no (JSN #0 mm), slow (0 , JSN , 0.5 mm), and fast (JSN $0.5 mm) progression of JSN. Post hoc Tukey-Kramer tests were used to assess pairwise comparisons when the omnibus test was significant. To determine the predictive value of serum UA for progression, receiver operating characteristic curves were constructed and areas under the curve (AUCs) computed (range 0-1, where 1 indicates perfect predictivity and 0.5 indicates random guessing). For these analyses, we defined nonprogression versus progression in the following 3 ways: 1) JSN #0 mm versus JSN .0 mm; 2) JSN #0 mm versus JSN .0.2 mm; and 3) JSN #0 mm versus JSN .0.5 mm. AUC values were compared against random models for significance using Delong's test. In addition, the relationship between the change in pain scores on the WOMAC and VAS measured at 24 months were correlated with serum UA levels to examine the potential relationship between serum UA levels and progression of pain.
RESULTS
Demographic characteristics. From among 146 completers of the original OA natural history study, 111 participants had medial disease at baseline. Of those, 88 had frozen serum of sufficient quantity to be enrolled in the current study. The demographic features of the enrolled patients are summarized in Table 1 . Twenty-seven of the 88 patients had also undergone baseline dynamic contrastenhanced MRI of the knee, with synovial volume measurements available for analysis. The demographic features and baseline synovial volumes in patients who enrolled in the original OA natural history study, but were lost to followup after the baseline assessment, were similar to those in our current study cohort (data not shown).
Relationship of serum UA levels to baseline OA severity and other characteristics. In an initial crosssectional analysis, serum UA levels did not correlate with baseline WOMAC pain scores (r 5 0.12, P 5 0.28) or VAS pain scores (r 5 0.08, P 5 0.48). Consistent with a previous study (17) , the serum UA levels also did not correlate with baseline OA severity measured as JSW (r 5 20.15, P 5 0.15) and K/L grade (F[3,84] 5 1.82, P 5 0.15). The ages of the patients, which ranged from 43 to 85 years, did not correlate with serum UA levels (r 5 0.14, P 5 0.19) in our cohort, despite reported associations in the literature. Consistent with previously published studies, serum UA levels significantly correlated with the BMI at study entry (r 5 0.23, P 5 0.03) and the mean serum UA levels in men were significantly higher than those in women (7.56 mg/dl versus 5.67 mg/dl; P , 0.01). There was no significant difference between baseline serum UA levels in the 8 patients taking a diuretic (all taking hydrochlorothiazide) and the patients not taking diuretics (6.10 mg/dl versus 6.32 mg/dl; P 5 0.63). Serum UA levels correlated significantly (r 5 0.44, P , 0.01) with MRI-determined baseline synovial volume on univariate analysis (Figure 1) . However, the synovial volume did not correlate with the serum UA level after multivariate adjustment for age, sex, and BMI, with the loss of association driven by sex (r 5 0.13, P 5 0.56). Because synovial volume has been suggested as a potential marker of OA progression (25), we next examined the relationship between serum UA levels and medial JSN.
Serum UA levels and 24-month radiographic disease progression. Serum UA levels were significantly correlated with the progression of OA measured as the medial JSN at 24 months (r 5 0.40, P , 0.01) (Figure 2A ). This correlation was retained (r 5 0.28, P 5 0.01) after controlling for age, sex, and BMI. Analysis of the data according to quartiles revealed an apparent step-off in 24-month JSN between the second and third quartiles ( Figure  2B ). One-way ANOVA revealed an overall difference in mean JSN between the 4 quartiles (F[3,84] 5 3.54, P 5 0.02), with significant differences in mean JSN between quartiles 1 and 4 (0.24 mm versus 0.94 mm; P 5 0.04) and between quartiles 2 and 4 (0.23 mm versus 0.94 mm; P 5 0.04). We therefore assessed the difference in JSN by dichotomizing the data across 3 possibly relevant cut points: the median serum UA level in the study population (5.85 mg/dl), the ACR serum UA treatment target for urate-lowering therapy among gout patients (6.0 mg/dl), and the solubility threshold for urate (6.8 mg/dl). We observed significant differences in mean JSN across all 3 cut points. After adjustment for age, sex, and BMI, significance was retained only around the cut point of 6.8 mg/dl (Table 2) . We next stratified patients by radiographic progression and analyzed for differences in serum UA levels between groups. We defined nonprogressors as individuals who had JSN of #0 mm over 24 months, slow progressors as those with 0 mm , JSN of ,0.5 mm over 24 months, and fast progressors as those with JSN of $0.5 mm over 24 months. We observed a significant difference in serum UA levels among the 3 progression groups (F[2,87] 5 5.51, P , 0.01). Post hoc testing confirmed a significant difference between the mean serum UA levels in nonprogressors versus fast progressors (5.8 mg/dl versus 7.1 mg/dl; P 5 0.02) and slow versus fast progressors (5.6 mg/dl versus 7.1 mg/dl; P , 0.01). In contrast, the difference between mean serum UA levels in nonprogressors versus slow progressors was not significant (P 5 0.69). After controlling for age, sex, and BMI, one-way ANOVA continued to confirm an overall significant difference in serum UA among the 3 progression groups (F[2,87] 5 3.64, P 5 0.03), with borderline significance for the difference between the mean serum UA level in nonprogressors versus fast progressors and in slow progressors versus fast progressors (P 5 0.07 and P 5 0.07, respectively). The discrepancy between the omnibus and post hoc test results was likely due to the greater statistical power of the omnibus test. As was the case for pain at baseline, the serum UA level did not correlate with the change in scores for the WOMAC pain (r 5 0.05, P 5 0.68) or VAS pain (r 5 20.04, P 5 0.72) over 24 months.
Additionally, we defined a range of JSN thresholds (according to the degree of 24-month JSN) as outcomes and used these to generate AUC curves and to determine r=0.44, p<0.01 (Table 3) . Exclusion of joint-widening artifacts. A minority of our patients experienced apparent widening of the medial compartment during the 2-year observation period. Although many investigators have ascribed such phenomena to a normal distribution within the measuring process (26, 27) , there are several reasons such widening might occur. Positioning errors or changes in weight bearing during imaging could hinder accurate joint space measurement. In our study, these sources of errors were mitigated through the use of standardized, fixed-flexion, weight-bearing imaging using a SynaFlexer device, which has been used in numerous other studies, including those of the Osteoarthritis Initiative (5, 7, 24, 28) . Additionally, in some cases, medial compartment widening can reflect mechanical shifts resulting from lateral compartment narrowing. This phenomenon, referred to as pseudowidening, could therefore reflect OA progression in the lateral compartment (29, 30 ) rather than any actual medial change. To assess for possible pseudowidening, we first determined the degree of lateral compartment change in patients with medial compartment widening versus those with medial compartment narrowing. We observed no significant difference in the lateral compartment change between these 2 groups (lateral JSN for those with medial compartment narrowing versus those with medial compartment widening 0.16 mm versus 0.16 mm, P 5 1.00).
To further examine the possibility that lateral compartment narrowing could have affected our medial compartment observations, we reanalyzed our data after first excluding all patients with both medial joint space widening (any degree) and substantial lateral compartment narrowing ($0.5 mm over 2 years). In this analysis, 9 patients were excluded, leaving 79 patients for medial compartment assessments (Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40069/abstract). We continued to observe a direct correlation between serum urate and 
DISCUSSION
To our knowledge, these results are the first to suggest that current baseline serum UA levels predict future progression of knee OA. Increased serum UA levels were associated with increased JSN, a widely used, Food and Drug Administration-endorsed marker of OA progression (31, 32) , in both univariate and multivariate analyses. Subjects with serum UA levels $6.8 mg/dl had significantly higher JSN at 24 months than did patients with serum UA levels of ,6.8 mg/dl (33) . Synovial tissue proliferation, as measured using gadolinium-enhanced MRI, also correlated with serum UA levels, although this correlation did not persist after multivariate analysis. This latter observation is consistent with reports that synovial volume correlates with radiographic OA (24) and that MRI-detected synovitis may be a risk factor for OA incidence and progression (34) (35) (36) . In contrast to several previous studies (37, 38) , the synovial volume did not correlate with OA pain in our study (data not shown), possibly because our MRI protocol involved global synovial examination, whereas pain has been most closely correlated with peripatellar synovitis (39, 40) . Finally, baseline serum UA levels distinguished both the mild progressors with JSN of .0.2 mm over 24 months and the fast progressors with JSN of .0.5 mm over 24 months from the nonprogressors through AUC analyses.
The observed association between serum UA levels and JSN could reflect a causal relationship, with secondarily elevated synovial fluid urate levels promoting cartilage damage, as synovial fluid is largely an ultrafiltrate of serum (17) . Chondrocytes express plasma membrane urate transporters, indicating that they can take up soluble urate with a potential for an intracellular pro-oxidant effect (41) . Alternatively, synovial fluid urate could act in its crystallized rather than soluble form. Indeed, our observation that an increased risk of JSN was best dichotomized around a serum UA level of 6.8 mg/dl (the saturation point for urate crystallization) supports a model in which MSU crystals promote synovitis (19, 42, 43) and cartilage disruption. Consistent with this possibility, UA has been shown to deposit on cartilage in patients with hyperuricemia who do not have gout (44) , and Martinon and others (41, 45) have demonstrated the ability of MSU crystals to activate the NLRP3 inflammasome and drive the generation of IL-1b, a major candidate cytokine in OA progression. Alternatively, OA progression could be accelerated intrinsically by chondrocyte death in a forward-feedback, UA-dependent cycle (17, (46) (47) (48) . As reported by Shi et al (47) , dying cells locally generate UA that, at concentrations sufficient to permit MSU crystallization, act as a danger signal to activate neighbor cell inflammatory responses. Although it is unlikely that chondrocyte death locally in an OA joint could be sufficient to increase systemic serum UA levels, it is possible that elevated serum and resultant synovial fluid UA concentrations create an environment in which chondrocyte death raises pericellular local UA concentrations sufficient to support MSU precipitation.
Finally, it is possible that the relationship between serum UA levels and OA progression is not causal, but instead, is due to a common predisposing factor(s). Given concerns for confounding, we controlled for age, sex, and BMI, and the correlation between JSN and serum UA levels persisted, revealing no significant effect of these factors. However, serum UA levels could predict progression of OA in a noncausative manner, reflecting processes that are not at present fully appreciated and therefore were not adjusted for in our model. It is worth noting that while our AUC analyses support an association between the serum UA level and OA progression, thus making it a candidate biomarker for progression, exploration of the efficacy of the serum UA level as a biomarker in the clinical setting would additionally require evaluation of its sensitivity and specificity tradeoff. Nevertheless, the AUC values we observed are consistent with those of other recently reported serum biomarkers of knee OA progression (5, 49) .
Strengths of our study include the use of a clinical laboratory for measuring serum UA levels in a standardized manner, the standardized acquisition of radiographs using the SynaFlexer positioning frame, the blinding of radiologists reading the radiographs for JSW and the MRI-based synovial volume, and a follow-up time of 2 years. Our cohort was also mostly community-based and likely representative of patients with knee OA in the general population. 1218 KRASNOKUTSKY ET AL Limitations of our study are that our population was restricted to patients with knee OA, a BMI of ,33 kg/ m 2 , and no gout, and the results may therefore not be generalizable to patients with knee OA without these features.
In contrast to JSN over 24 months, we observed no correlation between serum UA levels and JSW at study entry; however, our study did not set strict entry criteria on the duration of disease prior to the study, and the limitations of our data do not permit us to extrapolate in order to ascertain the rate of OA progression before study entry. We note, moreover, that analyses around the serum UA cut point of 6.8 mg/dl indicated that patients with supersaturated serum UA levels may have had significantly reduced JSW at entry ( Table 2) .
We did not measure all factors associated with OA progression, such as meniscal pathology or malalignment. We clinically determined the absence of gout and did not perform knee aspirations to confirm the absence of crystals. We included patients with symptoms and baseline K/L scores of $1, instead of the more conventionally defined K/L score $2 for defining OA, because a K/L score of 1 has recently been described as representing early OA (50) . Finally, our study, especially the subset of patients undergoing MRI, would have benefited from a larger sample size. Indeed, our data set for MRI analysis was normally distributed according to most, but not all, of the tests we applied. Prospective studies and greater sample sizes will be needed to assess the possibility of causality.
In conclusion, this is the first longitudinal study to report that serum UA levels may serve as a biomarker of OA progression. As serum UA measurements are inexpensive and readily obtainable, such results have the potential to affect the study of OA treatment by permitting the identification of patients who are more likely to experience progression for inclusion in investigational studies. Measurement of serum UA levels could also potentially provide a mechanism for determining the risk of progression and could facilitate monitoring the treatment of patients living with OA. Whether UA-lowering therapy could potentially help limit OA progression also deserves investigation.
